NCT05642923CompletedPhase 4
Post-COVID-19 Chronic Fatigue Syndrome
Source: ClinicalTrials.gov · Last updated 10 Mar 2025
Brief summary (registry, in English)
Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 528 (actual)
- First submitted
- 7 Dec 2022
- Start date
- 8 Jan 2023
- Primary completion date
- 1 Jun 2024
- Lead sponsor
- ClinAmygate
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05642923
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 528
- From 8 Jan 2023 to the primary completion date, 1 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- refusal
Who the study is looking for
- Age . 18
- Male or female
- Post-Covid-19 Fatigue
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asalam Coordinator of this site? Confirm its status | Maadi | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.